Please login to the form below

Not currently logged in
Email:
Password:

atomoxetine

This page shows the latest atomoxetine news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    The Medicines and Healthcare Products Regulatory Agency (MHRA) granted authorisation to expand the indication of Strattera (atomoxetine) to initiate treatment of ADHD in adults, where pre-existing symptoms during childhood can

  • Therapy focus: ADHD

    The most commonly prescribed non-stimulant is atomoxetine. It is believed to work by increasing the amount of noradrenaline (one of the brain's chemical messengers), which helps manage the symptoms ... The most common side effects of atomoxetine are

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics